Le Lézard
Classified in: Environment, Health, Science and technology
Subjects: PDT, RCY

IFF Pioneers Designed Enzymatic Biomaterials Technology Platform to Deliver Sustainable Biopolymers


OEGSTGEEST, Netherlands, June 29, 2023 /PRNewswire/ -- IFF today announced the launch of its new-to-the-world Designed Enzymatic Biomaterials (DEB) technology for the development of biobased materials at scale. Designed to deliver meaningful sustainability benefits ? with performance comparable or superior to fossil-based materials ? DEB technology helps to address growing preferences for environmentally-friendly, high-performance biopolymers.

The technology platform offers manufacturers the opportunity to meet regulatory changes and mounting consumer demands to replace traditional fossil-based synthetic polymers. DEB is poised to lead the rapidly progressing bio-revolution by unlocking purposeful and sustainable innovation across various applications and products in home care, personal care, fabric care and industrial markets.

"With the DEB technology platform, scientists can now build the functions of petroleum-based polymers into biopolymer materials directly ? customizing and fine-tuning polysaccharides to enable sustainable performance enhancements within the chosen application," said Wayne Ashton, VP of Home and Personal Care at IFF. "From my perspective, this is one of the most innovative technology platforms to launch industry-wide in the last 15 years."

Biomaterials derived from renewable raw materials are becoming a preferred option for many customers as they can be considerably more sustainable than their traditional, fossil-based counterparts. However, historically, biomaterials have demonstrated performance weaknesses, limiting their adoption and market penetration.

IFF's cutting-edge DEB technology utilizes advanced biotechnology to create unique, structurally diverse polysaccharides like those found in nature, but at scale, with an accuracy and consistency typically only found in traditional industrial polymers. Its new family of advanced tailored biomaterials uses only plant-based sugars, water and enzymes; to open up access to a range of materials with glycosidic linkage control, designed-in molecular weights and morphology.

The promising potential of this innovative technology platform has already been demonstrated across several industries.

IFF embeds its commitment to circular design across its business as a guiding principle toward creating responsible, sustainable, and closed-loop systems in which materials are reused and waste becomes a resource. The Company continues to seek partnerships with forward-thinkers to drive the bio-revolution. To learn more about how Designed Enzymatic Biomaterials from IFF are powering a new frontier in biomaterial innovation, visit here.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world ? from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.comTwitter , FacebookInstagram, and LinkedIn.

©2023 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with tm, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

Media contact:
Annemarieke Van Heeswijk 
Strategic Marketing & Communication 
+1 585 259 9486
[email protected] 

SOURCE IFF


These press releases may also interest you

at 10:45
eBlu Solutions, a leading provider of innovative technology solutions for the specialty healthcare industry, is pleased to announce the addition of Doug Lawrence to the Executive Leadership team in the role of Chief Revenue Officer. "We're not just...

at 09:18
NUVISTA Mental Health proudly announces its participation as a Gold Sponsor for the 2024 Ontario First...

at 09:05
Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, today announced the presentation of positive clinical data from CARDINAL?HF,...

at 06:05
Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at...

at 06:00
Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for use across a range of infectious disease, oncology,...

at 03:14
Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention on Wednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in...



News published on and distributed by: